Prof. Weimin Li: Pioneer of China's Early Lung Cancer Screening & C-Lung-RADS at West China Hospital

1. Clinical Leadership: Architect of China's Modern Pulmonary Medicine

Professor Weimin Li is one of the most revered clinical pulmonologists and healthcare leaders in Asia. Having served as President of West China Hospital of Sichuan University—consistently ranked among the top two medical centers in China—Professor Li has spearheaded transformative systemic reforms in respiratory medicine, transforming West China Hospital's Department of Pulmonary and Critical Care Medicine (PCCM) into an internationally benchmarked center for clinical research and patient care.

Renowned globally as the founding pioneer of China’s national early lung cancer screening and pulmonary nodule risk stratification architecture, Professor Li has dedicated his career to intercepting thoracic malignancies at their earliest, curative stages while preventing the widespread overtreatment of benign pulmonary lesions.

2. Primary Clinical Focus & Pulmonary Conditions Managed

Professor Weimin Li’s specialized clinical service serves as the apex national referral destination for complex respiratory dilemmas:

• Pulmonary Nodules & Ground-Glass Opacities (GGOs): High-precision differential diagnosis of solitary and multiple ground-glass nodules, part-solid lesions, and indeterminate sub-centimeter lung nodules using computerized volumetric and radiomic risk modeling.
• Early Lung Cancer Interception: Formulating individualized watchful waiting versus surgical resection protocols, preventing unnecessary lobectomies for indolent pre-invasive lesions (AAH and AIS).
• Complex & Refractory Pulmonary Infections: Diagnostic resolution and targeted therapeutic regimens for rare fungal infections (aspergillosis, cryptococcosis), non-tuberculous mycobacterial (NTM) lung diseases, and severe community-acquired pneumonias in immunocompromised hosts.
• Advanced Non-Small Cell Lung Cancer (NSCLC) MDT: Directing comprehensive multidisciplinary boards combining next-generation targeted tyrosine kinase inhibitors (TKIs), dual-immunotherapy combinations, and anti-angiogenic salvage therapies for complex stage III/IV patients.

3. Landmark Scientific Research: Nature Medicine, The BMJ & ERJ

Professor Li's epidemiological and translational research has systematically dismantled Western-centric screening paradigms that failed to capture Asian non-smoking populations:

• 2024 Nature Medicine: The C-Lung-RADS Classification: In this landmark paper, Professor Li’s team introduced the "China Lung-RADS" (C-Lung-RADS) risk classification system. Built upon massive multi-center cohorts, this model integrates low-dose CT morphology, non-smoking risk exposures (secondhand smoke, cooking oil fumes, air particulate metrics), and volumetric growth kinetics, demonstrating superior sensitivity and specificity compared to Western Lung-RADS guidelines.
• 2025 The BMJ: Methodology for Large-Scale Population Cohorts: Published gold-standard methodological protocols for prospective clinical cohorts, establishing international benchmarks for longitudinal disease tracking and multi-omic biobanking.
• 2026 European Respiratory Journal (ERJ): Chinese Baseline Eosinophil Dynamics: Defined the reference distribution of circulating eosinophils in Asian populations, refining the clinical diagnosis and biological targeted management of severe eosinophilic asthma and allergic bronchopulmonary aspergillosis (ABPA).
• Molecular Cancer: Non-Coding RNAs in Lung Adenocarcinoma: Decoded circular RNA signaling networks that promote microvascular invasion in early-stage lung cancers, providing actionable peripheral blood biomarkers for non-invasive risk assessment.

4. Transformative Innovations in Bedside Care

Professor Li’s clinical innovations have dramatically shifted real-world clinical trajectories for millions of individuals:

• Curbing Over-Screening and Unnecessary Thoracic Surgery: Prior to Professor Li’s C-Lung-RADS framework, tens of thousands of healthy Asian non-smokers with benign inflammatory nodules underwent premature invasive surgery. Professor Li’s standardized observational criteria successfully reduced unnecessary surgical resections by over 40% while maintaining a 98% early curable cancer detection rate.
• Multi-Omic Liquid Biopsies for Pulmonary Nodules: Integrating circulating tumor DNA (ctDNA) methylation panels with AI-assisted CT imaging to accurately distinguish early-stage malignant nodules from benign inflammatory granulomas.
• Rapid Pathogen Identification for Intractable Pneumonias: Standardized metagenomic next-generation sequencing (mNGS) directly from bronchoalveolar lavage fluid (BALF), enabling targeted antimicrobial de-escalation within 24 hours of admission.

5. Benchmark Clinical Case Scenarios

Professor Li’s consultation service is renowned for resolving ambiguous cases turned away by other tertiary centers:

• Case Scenario 1 (Multi-Focal Bilateral Ground-Glass Nodules): A 42-year-old female non-smoker presented with more than 15 bilateral ground-glass opacities, having been advised elsewhere to undergo bilateral staged lung resections. Professor Li performed quantitative volumetric doubling-time analysis combined with molecular liquid biopsy under the C-Lung-RADS protocol. Identifying the dominant lesion as an indolent minimally invasive adenocarcinoma while the remaining nodules were benign inflammatory foci, he recommended a single targeted sublobar wedge resection, fully preserving the patient's long-term pulmonary capacity.
• Case Scenario 2 (Diagnostic Rescue in Refractory Cavitary Lung Disease): An elderly patient presented with progressive bilateral cavitary lung lesions and respiratory failure unresponsive to multiple broad-spectrum antibiotics. Directed by Professor Li, targeted bronchoscopy with rapid mNGS identified a rare co-infection of Mycobacterium abscessus and Aspergillus fumigatus. A tailored multi-drug antimycobacterial and triazole regimen achieved complete radiographic clearing and clinical cure.

6. Accessing Professor Weimin Li for International Patients

For international patients seeking authoritative second opinions on pulmonary nodules, ambiguous chest CT findings, or comprehensive lung cancer management, structured clinical preparation ensures optimal evaluation:

1. Thoracic Imaging & Record Assembly: Complete thin-slice chest CT scans (with axial DICOM files and slice thickness <= 1.0 mm), serial historical CT imaging (essential for volumetric growth comparison), previous bronchoscopy or biopsy pathology reports, and molecular gene sequencing reports (EGFR, ALK, ROS1, KRAS, PD-L1).
2. Pre-Screening & Radiologic Review: Triage by senior pulmonologists to assess nodule characteristics (solid, part-solid, pure GGO) and prioritize urgent cases requiring clinical intervention versus structured longitudinal surveillance.
3. Physician Review & Strategic Roadmap: Authorized evaluation of records by Professor Li’s specialized pulmonary committee to establish definitive diagnostic probabilities and formulate an individualized care trajectory.
4. Concierge & Inpatient Support: For admitted patients, dedicated support including priority bronchoscopy and imaging scheduling, bilingual medical escort, and coordinated follow-up surveillance.

7. Inquire & Request a Clinical Assessment

China Medical Concierge - Shanghai (CMCS) is an independent health management and medical concierge service. We connect international patients and expatriates with leading specialists and premier national academic medical centers across China.

To inquire about case reviews, pulmonary nodule evaluations, or coordination with Professor Weimin Li’s pulmonary team, please reach out directly through our official channels: